Form 4: BridgeBio Pharma Executive Sells 1,026 Shares of Common Stock

Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, Inc., sold 1,026 shares of common stock at a price of $38.5079 on May 2, 2025.

Summary

• On May 2, 2025, Maricel Apuli, the Chief Accounting Officer of BridgeBio Pharma, Inc. (BBIO), sold 1,026 shares of the company's common stock.
• The transaction was executed at a price of $38.5079 per share.
• Following the reported transaction, Apuli directly owns 147,639 shares of BridgeBio Pharma's common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an insider stock sale. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, like officers and directors, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects. However, insider sales don't always indicate a negative outlook, as they can be motivated by personal financial planning needs.

Comparison to Industry Standards

• It's common for executives at publicly traded companies like BridgeBio Pharma to periodically sell shares for personal financial management.
• The sale of 1,026 shares by the Chief Accounting Officer is a relatively small transaction compared to the total outstanding shares of the company.
• Comparable companies such as Amgen, Gilead Sciences, and Vertex Pharmaceuticals also see regular Form 4 filings from their executives.

Stakeholder Impact

• The sale of shares by a company executive can sometimes create uncertainty among shareholders, although this particular transaction is unlikely to have a significant impact due to its small size.

Key Dates

Keywords

Form 4, BBIO, BridgeBio Pharma, Maricel Apuli, stock sale, Chief Accounting Officer, insider trading